Welcome to our dedicated page for ATE news (Ticker: ATE), a resource for investors and traders seeking the latest updates and insights on ATE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ATE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ATE's position in the market.
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) announced its participation in several investor conferences in March 2021. Key events include the H.C. Wainwright Global Life Sciences Conference on March 9, Roth Capital Partners Annual Conference on March 15, and Oppenheimer & Co. 31st Annual Healthcare Conference on March 16, followed by the Maxim Group Emerging Growth Virtual Conference on March 17. Webcasts will be available on-demand on the company’s website, where replays can be accessed for 90 days.
Antibe is developing safer therapies using its hydrogen sulfide platform, targeting conditions like osteoarthritis and inflammatory bowel disease.
Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF) has reported its financial results for the quarter ending December 31, 2020. Notable achievements include preparations for Phase III trials of otenaproxesul, strategic licensing with Nuance Pharma for the Greater China region, and a rise in cash reserves to $15.4 million. Revenue increased to $2.8 million, up from $2.6 million, primarily due to Citagenix. However, the net loss widened to $6.5 million from $4.2 million, reflecting higher R&D expenses of $3.4 million. Overall, Antibe is focusing on expanding its pipeline and solidifying its market position.
Antibe Therapeutics has licensed otenaproxesul to Nuance Pharma for commercialization in Greater China, which includes China, Hong Kong, Macau, and Taiwan. The agreement grants Nuance exclusive rights and entails US$100 million in milestone payments, comprising US$20 million upfront and US$80 million based on development and sales milestones. Nuance will cover clinical and regulatory costs. The partnership aims to leverage China’s growing demand for innovative pain management therapies, particularly nonsteroidal anti-inflammatory drugs.
Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF) announced the appointment of Dr. Don Haut to its Partnering Advisory Team. Dr. Haut, previously Chief Business Officer at AskBio, brings extensive experience in business development with over $8 billion in transaction completions. His strategic expertise is expected to enhance Antibe's business capabilities and accelerate partnering activities in 2021. Antibe is focused on developing safer nonsteroidal anti-inflammatory drugs using its unique hydrogen sulfide platform, with lead drug otenaproxesul entering Phase III trials.
Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF) has initiated discussions to amalgamate with Antibe Holdings Inc. This move aims to consolidate the intellectual property (IP) ownership of its drug development platform, potentially enhancing value for partners and investors. CEO Dan Legault highlighted the importance of full IP ownership, noting achievements like human proof-of-concept for otenaproxesul and promising preclinical data for other assets. This strategy complements recent corporate activities, including a TSX graduation and share consolidation.
